Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04895358
Title	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme Corp.
Indications	Her2-receptor negative breast cancer
Therapies	Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Daunoxome + Pembrolizumab Daunoxome Paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| AUT